摘要
目的：评价复方苦参注射液联合化疗治疗晚期胃癌的疗效、KPS评分及对T细胞亚群的作用。方法：将90例晚期胃癌患者随机分为治疗组（复方苦参注射液＋化疗组）和对照组（化疗组）。对照组应用多西他赛、奥沙利铂、氟尿嘧啶联合化疗，治疗组同时加用复方苦参注射液20ml／d静滴，连用2周，3周为一周期。结果：治疗组临床获益率（CR＋PR＋SD）77．08％，明显优于对照组为（61．90％）（P=0．029）；治疗组、对照组Kamofsky评分提高率分别为60．4％和42．9％，两组对比有显著性差异（P=0．024）；治疗组CD4及CD8阳性细胞的百分率分别是39．2±1．9和26．5±1．4，对照组分别是30．8±1．7和23．0±1．8，治疗组高于对照组（P=0．000）。结论：复方苦参注射液联合化疗治疗晚期胃癌有改善生活质量，提高免疫功能，增强化疗效果的作用。
Objective： To evaluate the effective of treating advanced gastric cancer with Fufangkushen injection plus chemotherapy, KPS （scores of quality of life） and T cell subsets. Methods： 90 cases of advanced gastric cancer are randomly divide in treatment group （Fufangkushen injection＋chemotherapy） and control group （chemotherapy）. control group were treated with joint chemotherapy of doceta -xel, oxaliplatin, fluorouracil, treatment group bases on joint chemotherapy add to Fufangkushen injection （20ml/d,d1-14）, used 2 weeks, 3 weeks are one treatment. Results： Treatment group clinical benefit rate （CR＋PR＋SD） is 77.08%, is better than control group （61.90%） （ P=0.029）; Karnofsky score increased rate of treatment group and control group are 60.4%, 42.9%, two groups have significant defference （P=0.024）; treatment group positive cells rate of CD4 and CD8 are 39.2±1.9 and 26.5±1.4, control group are 30.8±1.7and 23.0il.8, treatment group is higher than control group （P=0.000）. Conclusion： Treating advanced gastric cancer with Fufangkushen injection plus chemotherapy can improve quality of life, immune function, enhance the effect of chemotherapy.
出处
《中医临床研究》
2010年第23期63-64,共2页
Clinical Journal Of Chinese Medicine
